logo

SILO

Silo Pharma·NASDAQ
--
--(--)
--
--(--)
2.13 / 10
Underperform

Silo Pharma's fundamentals are subpar (2.1/10). Key weaknesses include stagnant operating revenue growth (0% YoY) and an inventory turnover ratio of 47.88, while a 15.5 interest-coverage ratio offers some cushion. The negative PB-ROE (-0.27) and low revenue-matching score (-4.43) further highlight structural issues, supporting a guarded stance.

Fundamental(2.13)SentimentTechnical

Analysis Checks(6/10)

Revenue-MV
Value-4.43
Score1/3
Weight10.74%
1M Return3.98%
Total operating revenue (YoY growth rate %)
Value0.00
Score1/3
Weight-1.30%
1M Return-0.60%
Inventory turnover ratio
Value47.88
Score2/3
Weight-2.58%
1M Return-1.23%
Profit-MV
Value0.47
Score2/3
Weight24.93%
1M Return8.99%
PB-ROE
Value-0.27
Score2/3
Weight33.38%
1M Return10.90%
Interest coverage ratio (EBIT / Interest expense) (%)
Value15.51
Score2/3
Weight-2.69%
1M Return-1.25%
Operating revenue (YoY growth rate %)
Value0.00
Score1/3
Weight-1.13%
1M Return-0.52%
Asset-MV
Value-0.51
Score0/3
Weight16.84%
1M Return6.58%
Net profit / Total profit (%)
Value100.00
Score2/3
Weight-2.12%
1M Return-0.98%
Cash-MV
Value-0.07
Score2/3
Weight23.93%
1M Return8.80%
Is SILO undervalued or overvalued?
  • SILO scores 2.13/10 on fundamentals and holds a Premium valuation at present. Backed by its -66.64% ROE, -7041.12% net margin, -0.83 P/E ratio, 0.81 P/B ratio, and 21.55% earnings growth, these metrics solidify its Underperform investment rating.